Successful completion of the first group in the intra-tumour light dose escalation part of the ENHANCE study

Oslo, 24 January 2014 - PCI Biotech (PCIB) the Norwegian biopharmaceuticalcompany, reported today that the treatment evaluation of the first group in theintra-tumour light dose escalation part of the ENHANCE study has been completed.  ENHANCE is a phase II study of Amphinex® in combination with thecytotoxic agent bleomycin in recurrent head and neck cancer patients. No safety concerns were raised and a clear but insufficient tumour response was seen atthis light dose level. The first level of the light dose escalating part of the trial is now completed.

A Dose Review Committee (DRC) of clinical experts and company representativeshas been established to evaluate the results and provide recommendation for thecontinuation of the study. The DRC has recommended that the light dose isescalated according to the protocol. Patients for the next light dose level arecurrently being screened and will be treated with Amphinex® as soon as possible.